You searched for "ophthalmic"
75th Anniversary year of the first intraocular lens implant
The 29th of November 2024 marks the 75th anniversary of the first intraocular lens implant by our Founder, Sir Harold Ridley FRS. The United Kingdom & Ireland Society of Cataract & Refractive Surgeons (UKISCRS) is marking the event with a...Should points for simulated surgery be removed from the ophthalmology ST1 evidence folder?
The benefits of the Eyesi surgical simulator by Haag-Streit UK for early career ophthalmology speciality trainees are well-established, allowing for the practice of cataract and vitreoretinal surgery in a controlled, risk-free environment. Whilst the Eyesi is an invaluable resource for...Audiology and ophthalmology: A comparative perspective on diagnostics and patient care
I’m here with Chris Gordon and Anthony Vukic from Gloucestershire Hospitals NHS Foundation Trust to find out how two professions that may appear unrelated on the surface actually have a lot in common. Some of this article might surprise you....Gambia-Swansea Partnership: Technical support in our 16-year partnership
I have been involved in the Gambia-Swansea VISION 2020 LINK now for more than 16 years. I hope that this article will be of some interest to anyone considering volunteering overseas, as part of a LINK or in any other...Eyeviews Podcast
eyeviews presents conversations on seeing and sight loss, released by Eye News magazine. Hosted by Lorcan Butler, this podcast covers a wide and diverse range of topics related to ophthalmology, optometry and more. Eye Views is available on Spotify, Apple...Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals
Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...
